Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products
2023; Elsevier BV; Volume: 25; Issue: 6 Linguagem: Inglês
10.1016/j.jcyt.2023.01.008
ISSN1477-2566
AutoresMeghan Logun, Maxwell B. Colonna, Katherine P. Mueller, Divya Ventarapragada, Riley Rodier, Chaitanya Tondepu, Nicole J. Piscopo, Amritava Das, Stacie A. Chvatal, Heather B. Hayes, Christian M. Capitini, Daniel J. Brat, Theresa Kotanchek, Arthur S. Edison, Krishanu Saha, Lohitash Karumbaiah,
Tópico(s)Viral Infectious Diseases and Gene Expression in Insects
ResumoChimeric antigen receptor (CAR) T cells have demonstrated remarkable efficacy against hematological malignancies; however, they have not experienced the same success against solid tumors such as glioblastoma (GBM). There is a growing need for high-throughput functional screening platforms to measure CAR T-cell potency against solid tumor cells.
Referência(s)